Preclinical pharmacology of angiotensin II receptor antagonists: Update and outstanding issues

American Journal of Hypertension

Volumn 10, Issue 12 II SUPPL., 1997, Pages

  Johnston, Colin I ^a   Risvanis, John ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin converting enzyme inhibitors; Heart failure; Hypertension; Irbesartan; Renin inhibitors

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IRBESARTAN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; COMPETITIVE INHIBITION; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0031418447     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00388-9     Document Type: Article

References (22)

1. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy A review of the literature and pathophysiology . Ann Intern Med. 117:1992;234-242.
2. Lacourcière Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens. 12:1994;1387-1393.
3. Jullierat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertens. 16:1990;564-572.
4. Husain A. The chymase-angiotensin system in humans. J Hypertens. 11:1993;1155-1159.
5. Urata H, Nishimura H, Ganten D. Chymase-dependent angiotensin II forming system in humans. Am J Hypertens. 9:1996;277-284.
6. Yamada H, Fabris B, Allen AM, et al. Localization of angiotensin converting enzyme in the rat heart. Circ Res. 168:1991;141-149.
7. Zisman LS, Abraham WT, Meixell GE, et al. Angiotensin II formation in the intact human heart. J Clin Invest. 96:1995;1490-1498.
8. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 349:1997;747-752.
9. Zhou J, Allen AM, Yamada H, et al: Localization and properties of the angiotensin-converting enzyme and angiotensin receptors in the heart, In Lindpainter K, Ganten D, (eds): The Cardiac-Renin Angiotensin system. Futura Publishing Co., Mt. Kisco, NY, 1994, pp 63-88.
10. Angiotensin II receptors and angiotensin II receptor antagonists. Pharm Rev. 45:1993;206-252.
11. Johnston CI. Angiotensin receptor antagonists focus on losartan . Losartan. 346:1995;1403-1407.
12. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors target for drug research? J Hypertens. 12:(suppl 2):1994;S1-S5.
13. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Cell Biol. 93:1996;156-160.
14. 1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol. 251:1994;143-150.
15. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 265:1993;826-834.
16. 1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys. Br J Pharmacol. 111:1994;145-150.
17. 1) blockade in the human forearm. Blood Pressure. 5:(suppl 2):1996;65-70.
18. 1 receptor antagonist in hypertensive rat models. Eur J Pharmacol. 264:1994;307-316.
19. Hayakawa H, Coffee K, Guerra J, Raij L. Cardio-renal protective effects of the angiotensin II receptor antagonist, irbesartan, in salt-sensitive hypertension (abst). Am J Hypertens. 10:(4, part 2):1997;94A.
20. Ziai F, Ots M, Provoost AP, et al. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int. 50:(suppl):1996;S132-S136.
21. Vacher E, Fornes P, Richer C, et al. Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development. J Hypertens. 13:1995;675-682.
22. CP rats (abst). J Hypertens. 14:(suppl):1996;S137.